| Rachael Beth Turner, MD, PHD | |
|
601 Elmwood Ave, Box Med, Rochester, NY 14642-0001 | |
| (585) 275-2222 | |
| Not Available |
| Full Name | Rachael Beth Turner |
|---|---|
| Gender | Female |
| Speciality | Medical Oncology |
| Experience | 11 Years |
| Location | 601 Elmwood Ave, Rochester, New York |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013250232 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 279443 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Strong Memorial Hospital | Rochester, NY | Hospital |
| Highland Hospital | Rochester, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hematology Clinical Group | 4486618576 | 72 |
| University Of Rochester | 5799699088 | 814 |
News Archive
Beth Israel Deaconess Medical Center (BIDMC) has been awarded $38.2 million in funding from the National Institutes of Health (NIH) as part of the American Recovery and Reinvestment Act of 2009 (ARRA).
Scientists from the Tumor Immunotherapy and Microenvironment research group led by Dr Bassam Janji at the Luxembourg Institute of Health Department of Oncology, and the Swedish pharma company Sprint Bioscience published the results of an innovative approach that turns "cold" tumors "hot". "Cold", immune-desert tumors are classically immunotherapy-resistant.
The insurer said it expects to add more customers to its Medicare Advantage and individual plan businesses. Meanwhile, a few hospitals say they are doing simple surgeries for some uninsured patients for free to keep their problems from turning into emergencies that would be more expensive to treat, and those who developed meningitis as a result of tainted products seek compensation.
On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
› Verified 2 days ago
| Entity Name | University Of Rochester |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710226824 PECOS PAC ID: 5799699088 Enrollment ID: O20031201000019 |
News Archive
Beth Israel Deaconess Medical Center (BIDMC) has been awarded $38.2 million in funding from the National Institutes of Health (NIH) as part of the American Recovery and Reinvestment Act of 2009 (ARRA).
Scientists from the Tumor Immunotherapy and Microenvironment research group led by Dr Bassam Janji at the Luxembourg Institute of Health Department of Oncology, and the Swedish pharma company Sprint Bioscience published the results of an innovative approach that turns "cold" tumors "hot". "Cold", immune-desert tumors are classically immunotherapy-resistant.
The insurer said it expects to add more customers to its Medicare Advantage and individual plan businesses. Meanwhile, a few hospitals say they are doing simple surgeries for some uninsured patients for free to keep their problems from turning into emergencies that would be more expensive to treat, and those who developed meningitis as a result of tainted products seek compensation.
On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
› Verified 2 days ago
| Entity Name | Hematology Clinical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821049396 PECOS PAC ID: 4486618576 Enrollment ID: O20041118000124 |
News Archive
Beth Israel Deaconess Medical Center (BIDMC) has been awarded $38.2 million in funding from the National Institutes of Health (NIH) as part of the American Recovery and Reinvestment Act of 2009 (ARRA).
Scientists from the Tumor Immunotherapy and Microenvironment research group led by Dr Bassam Janji at the Luxembourg Institute of Health Department of Oncology, and the Swedish pharma company Sprint Bioscience published the results of an innovative approach that turns "cold" tumors "hot". "Cold", immune-desert tumors are classically immunotherapy-resistant.
The insurer said it expects to add more customers to its Medicare Advantage and individual plan businesses. Meanwhile, a few hospitals say they are doing simple surgeries for some uninsured patients for free to keep their problems from turning into emergencies that would be more expensive to treat, and those who developed meningitis as a result of tainted products seek compensation.
On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
› Verified 2 days ago
| Entity Name | Gyn Oncology Group Of The University Of Rochester |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033129044 PECOS PAC ID: 6800836784 Enrollment ID: O20050510000867 |
News Archive
Beth Israel Deaconess Medical Center (BIDMC) has been awarded $38.2 million in funding from the National Institutes of Health (NIH) as part of the American Recovery and Reinvestment Act of 2009 (ARRA).
Scientists from the Tumor Immunotherapy and Microenvironment research group led by Dr Bassam Janji at the Luxembourg Institute of Health Department of Oncology, and the Swedish pharma company Sprint Bioscience published the results of an innovative approach that turns "cold" tumors "hot". "Cold", immune-desert tumors are classically immunotherapy-resistant.
The insurer said it expects to add more customers to its Medicare Advantage and individual plan businesses. Meanwhile, a few hospitals say they are doing simple surgeries for some uninsured patients for free to keep their problems from turning into emergencies that would be more expensive to treat, and those who developed meningitis as a result of tainted products seek compensation.
On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rachael Beth Turner, MD, PHD 601 Elmwood Ave, Box Med, Rochester, NY 14642-0001 Ph: (585) 275-2222 | Rachael Beth Turner, MD, PHD 601 Elmwood Ave, Box Med, Rochester, NY 14642-0001 Ph: (585) 275-2222 |
News Archive
Beth Israel Deaconess Medical Center (BIDMC) has been awarded $38.2 million in funding from the National Institutes of Health (NIH) as part of the American Recovery and Reinvestment Act of 2009 (ARRA).
Scientists from the Tumor Immunotherapy and Microenvironment research group led by Dr Bassam Janji at the Luxembourg Institute of Health Department of Oncology, and the Swedish pharma company Sprint Bioscience published the results of an innovative approach that turns "cold" tumors "hot". "Cold", immune-desert tumors are classically immunotherapy-resistant.
The insurer said it expects to add more customers to its Medicare Advantage and individual plan businesses. Meanwhile, a few hospitals say they are doing simple surgeries for some uninsured patients for free to keep their problems from turning into emergencies that would be more expensive to treat, and those who developed meningitis as a result of tainted products seek compensation.
On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.
› Verified 2 days ago
Amy Bodrog, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1425 Portland Ave, Rochester, NY 14621 Phone: 585-922-4020 Fax: 585-922-4622 | |
Natalia Golub, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 30 Hagen Dr Ste 320, Rochester, NY 14625 Phone: 585-922-1900 | |
Hanan Ibrahim Sheikh Ibrahim, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1415 Portland Ave Ste 200, Rochester, NY 14621 Phone: 585-922-0390 Fax: 585-922-0395 | |
Numra Aslam Bajwa, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1425 Portland Ave, Rochester, NY 14621 Phone: 585-922-5067 Fax: 716-862-1871 | |
Dr. Prakash Upreti, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1425 Portland Ave, Rochester, NY 14621 Phone: 295-029-8769 | |
William M Valenti, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 259 Monroe Avenue, Rochester, NY 14607 Phone: 585-545-7200 Fax: 585-244-6456 | |
Ms. Terri Winter, N.P. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 250 Crittenden Blvd, Box 617, Rochester, NY 14642 Phone: 585-275-2662 Fax: 585-276-0149 |